Dr. Umar

This original study investigated the gut microbiome in Australian Parkinson’s disease and how microbial alterations in people with Parkinson’s disease (PwP) may influence functional metabolic pathways relevant to neurodegeneration. Using 16S rRNA sequencing of the V3–V4 regions, the researchers compared microbial composition, alpha and beta diversity, and predicted KEGG metabolic pathways between […]

This study identifies distinct dysbiosis in the colonic microbiota in Parkinson’s disease, marked by reduced butyrate-producing bacteria and increased proinflammatory taxa, suggesting microbial contributions to intestinal inflammation and alpha-synuclein pathology.

This study identifies major gut microbiome alterations in Parkinson’s disease, especially reduced Prevotellaceae and increased Enterobacteriaceae linked to motor phenotype, suggesting clinically relevant microbial signatures.

Study showing gut microbiota and Parkinson’s disease are mechanistically linked through SCFA-driven microglial activation, aSyn pathology, and motor impairment in mouse models and humanized microbiota experiments.

This study identifies Parkinson’s disease gut microbiome signatures involving reduced SCFAs and loss of key butyrate-producing taxa, highlighting microbial shifts that may influence enteric and neurological function.

This study identifies a distinct gut microbiota signature in Parkinson’s disease, marked by loss of SCFA-producing taxa and enrichment of inflammatory pathobionts correlated with disease severity.

This study identifies distinct gut microbiota signatures in Parkinson disease, particularly elevated Lactobacillaceae, Barnesiellaceae, and Enterococcaceae, supporting a possible enteric contribution to PD pathophysiology.

Early-stage PD patients show distinct gut microbial, functional, and viral signatures, including reduced Prevotella copri, impaired β-glucuronate pathways, increased tryptophan metabolism, and decreased viral abundance, forming a robust Parkinson’s disease microbiome signature.

This study identified reduced diversity and distinct taxonomic shifts in gut microbiota in Parkinson’s disease, highlighting microbial patterns linked to inflammation and α-synuclein biology.

This study outlines distinct Parkinson’s disease gut microbiome signatures, revealing altered bacterial taxa and metabolic pathways independent of medications and confounders, with strong implications for SCFA metabolism, xenobiotic processing, and biomarker development.

Study of gut microbiota in Parkinson’s disease revealed major taxonomic shifts, loss of butyrate-producing bacteria, and phenotype-specific microbial associations, suggesting potential biomarker value.

This original research article examined fecal microbiota in Chinese Parkinson’s disease to determine how gut microbial communities differ between patients with Parkinson’s disease (PD) and healthy controls. Using high-throughput Illumina MiSeq sequencing of the 16S rRNA V3–V4 region, the investigators analyzed fecal samples from matched couples—each PD patient and their cohabiting spouse—to […]

This study reveals distinct gut microbiome alterations in Parkinson’s disease and idiopathic REM sleep behavior disorder, highlighting early microbial signatures and identifying novel taxa relevant to disease mechanisms. Nasal microbiota showed minimal diagnostic value.

This study identifies distinct gut microbiome alterations in North-Eastern Han Chinese adults with Parkinson’s disease, highlighting bacterial signatures involving Verrucomicrobiaceae, Ruminococcaceae, and reduced Prevotellaceae that may contribute to gut–brain axis dysfunction.

This study identified gut microbiota dysbiosis in Parkinson’s disease featuring reduced SCFA-producing taxa and increased pro-inflammatory bacteria, correlating strongly with motor severity.

This study examined gut microbiota in Parkinson’s disease, identifying reduced Lachnospiraceae as an early signature and linking microbial shifts to motor and cognitive severity.

Study defines microbial alterations in Parkinson’s disease gut microflora, highlighting reduced SCFA-producing taxa, increased Rikenellaceae and Turicibacter, and associations with disease severity and medication.

The study links microbiome dysbiosis, elevated LPS-producing taxa and impaired intestinal integrity with α-synuclein–related pathology, showing how gut inflammation may trigger or worsen Parkinson’s disease.

This study examined how Parkinson’s disease and dopaminergic medications shape the gut microbiome, revealing reduced beneficial taxa, increased Clostridiales XI organisms, and strong medication-specific microbial signatures with implications for inflammation and drug metabolism.

This study shows that gut microbiota differs between Parkinson’s disease patients and healthy controls in Northeast China, with reduced richness, altered β-diversity, elevated Akkermansia, and reduced Lactobacillus, linking microbiome changes to clinical severity.

Altered gut microbiota in Parkinson’s disease revealed reduced Prevotella, increased pro-inflammatory taxa, and cytokine elevations linked to motor severity, highlighting gut–immune contributions to neurodegeneration.

Early Parkinson’s disease exhibits distinct alterations in the oral microbiome, including neurotransmitter-related taxa and inflammatory organisms, offering potential biomarkers and mechanistic insights.

Longitudinal analysis revealed stable, reproducible microbiome alterations in Parkinson’s disease, especially reduced Prevotella abundance in Parkinson’s disease, highlighting a persistent microbial signature with possible diagnostic relevance.

The study links intestinal microbiota and weight loss in Parkinson’s disease, identifying fatty acid biosynthesis pathways in weight-loss patients and inflammatory pathways in stable-weight patients, suggesting microbial influence on metabolic changes.